Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Barrow Hanley Credit Partners: Lens on Credit Series | Credit Markets: Then vs. Now

Credit Markets: Then vs. Now Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Credit Markets: Then vs. Now

Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies.

More about Chet Paipanandiker, Portfolio Manager

More about Nick Losey, Portfolio Manager

Video TranscriptExpand ↓

Yes the credit markets have been in a pretty interesting place over the last three years. We've basically been through a mini credit cycle. If you think back to what happened, go back to the early part of 2020, basically at a global pandemic. And by virtue of the Fed stepping in and helping to solve capital markets as well as work to develop a vaccine, we actually saw a credit markets do a complete about face. We started out with companies contemplating zero revenues and by the latter part of the year with the benefit of a vaccine, as well as with the benefit of companies terming out maturities and raising cash, basically enhancing their liquidity. You saw revenues come back and you saw companies with pretty pumped up liquidity facilities. So as a result, they were able to better handle the stresses that were occurring at the time, whether it's because of revenues, labor availability or inflation. At the same time, something else was happening to the consumer. You basically saw the consumer also see its balance sheet get pumped up by virtue of the stimulus checks that came through. And so pretty much you went through this period of extreme volatility where companies and consumers were in a bad place. They basically didn't about ship and everyone ended up in a generally better place from a fundamental perspective. And so what did that do with credit markets? We certainly saw a swoon to the downside when COVID occurred. Credit markets rebounded. As you went to the earlier part of this year, we ended into a period of new stress, basically Russia invading Ukraine. And it's interesting to see what happened to credit spreads during that time frame. So on a year to date basis, what you basically saw was double B's were underperforming because the Fed was raising rates. At the same time, credit risk was actually outperforming single B's and triple C's on a relative basis to double B's. But come April of 2022, they actually started to reverse, and you saw double B's start to outperform. And there was an indication that credit stress might actually be more of a concern on people's minds. And so you actually saw single B's and triple C's begin to underperform on a relative basis to double B's. What we are seeing in the credit markets today is, you know, something that we hadn't seen in a number of decades in the past. You know, when we think about what's going on in the environment right now, we came into the beginning of the year where inflation started to increase. And then with Russia, Russia invading Ukraine, basically that kind of added a spark to kind of really set the fire on inflation. And now we're sitting it roughly at 9% year over year inflation rate. We haven't really seen this type of inflation environment for upwards of four decades. So when you think about the investing world, there are not that many participants in the markets today that have actually directly experienced what we are experiencing now or are likely to experience if inflation stays at very high levels for the foreseeable future. Now, when we think about inflation, basically we were concerned about the inflationary environment going into the beginning of this year. So we really pulled back on our exposure to duration, longer duration assets and have benefited, because of that. Now we do not believe that we are going to run rate at a 9% inflation rate. You're already starting to see a lot of your data points tick over, but do not believe that we're going back to this one to 2% inflation rate environment.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Two Radiology Deals Signal Focus on Coverage, Not Scanners

Two Radiology Deals Signal Focus on Coverage, Not Scanners

Colorado Imaging Associates and TRA Medical Imaging announced Sept. 8, 2026 that they are forming Affiliated Radiology to expand physician coverage for a shared health system client, Radiology Business reported. Separately, Align Capital Partners said in late May 2026 it agreed to acquire Boise-based Heritage Imaging, a mobile diagnostic imaging provider operating in 14 states, according to Radiology Business.

  • 01Affiliated Radiology was formed by combining Colorado Imaging Associates and TRA Medical Imaging to expand physician coverage for a shared health system client.
  • 02Heritage Imaging operates mobile diagnostic units across 14 states, providing PET-CT, MRI, nuclear medicine, ultrasound and echocardiography to critical access hospitals and community clinics.
  • 03Health system sourcing teams should request service-level commitments, credentialing procedures, cross-location read routing, and PACS/RIS/EHR integration details before contracting with coverage-focused or mobile imaging arrangements.

Sep 12, 2026

Dr. Sotirios Stathakis: A TheraPanacea Customer Interview

Dr. Sotirios Stathakis: A TheraPanacea Customer Interview

Dr. Sotirios Stathakis, Chief of Physics at Mary Bird Perkins Cancer Center, discusses how the facility integrated TheraPanacea's AI tools including MRI Box and Annotate to streamline workflows and improve treatment planning. The implementation, which began in 2023, demonstrates how thoughtful AI adoption enhances quality assurance and operational efficiency in cancer care.

  • 01MRI-only workflow adoption via MRI Box reduces need for CT scans, particularly for prostate and bladder cancer treatment
  • 02Annotate tool used in 40-45% of cases for head, neck, and abdominal procedures, offering precision beyond manual contouring
  • 03AI implementation strategy: start with control cases, build team confidence, then gradually expand to ensure smooth adoption and staff acceptance

Sep 11, 2026

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz, Chief Medical Physicist at Texas Oncology, brings both professional expertise and personal experience as a breast cancer survivor to her role in advancing cancer care. Over 23 years at Texas Oncology, she champions technology adoption and AI integration in oncology while emphasizing the importance of human oversight in clinical applications.

  • 01Dr. Rosencranz is a five-year breast cancer survivor whose personal experience informs her approach to patient empathy and personalized care delivery.
  • 02AI applications in oncology like auto-contouring and treatment planning show significant advancement potential, but require consistent human leadership and oversight.
  • 03Texas Oncology reaches many demographics, including rural areas where travel to urban centers is hard, while staying current with the highest technology available.

Sep 11, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512